> When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014).[14] At the time of initial approval, only about 1,000 patients in the US had an indication for blinatumomab.
I take it they prefer to pump chemotherapy poison ito patients for financial reasons?
> When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014).[14] At the time of initial approval, only about 1,000 patients in the US had an indication for blinatumomab.
I take it they prefer to pump chemotherapy poison ito patients for financial reasons?